Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>Terms & Conditions
  Terms & Conditions


Press Releases & Product Announcements

Please send all press releases and product announcements to pr@technologynetworks.com Wherever possible, press releases should be emailed as a Microsoft Word attachment or embedded in the email itself. Images should be sent as separate attachments. Where possible please insert the name(s) of the community(ies) that you wish the press release to be published on into the subject line of the email.

For a full list of all Technology Networks’ communities please click here

Submitting Application Notes

By submitting your application notes to us for online publication you are agreeing to the Terms and Conditions for the application notes section of Technology Networks' communities and, confirming that you have the required copyright to submit these application notes.

Application notes should be submitted to apps@technologynetworks.com preferably as a PDF, if not as a Microsoft Publisher or PowerPoint file. A 40 - 70 word summary must be sent with each application note submitted.

The name(s) of the website(s) that you wish the application note to be published on should be entered into the subject line of the email. For a full list of all Technology Networks’ communities please click here

Before submitting an application note for online publication please read the terms and conditions below.

Submitting a Poster

Posters submitted by academics and from not-for-profit organizations will be published free of charge. For commercial companies there will be an administration charge of $200 for each poster published. Please contact Kelly Giles for more information.

By submitting your poster to us for online publication you are agreeing to the Terms and Conditions for the Posters section of Technology Networks' communities and confirming that you have the required copyright to submit these posters.

Posters should be submitted using the online submission form which is located within the posters section of each website, (click “submit poster” link). The poster needs to be submitted as a PDF or Microsoft PowerPoint file. A 40 – 70 word summary must be submitted along with the poster.

If you have any problems with you submission, please contact posters@technologynetworks.com, stating the name of the website you wish to publish your poster on in the subject line.

Before submitting a poster for online publication please read the terms and conditions below.

TERMS AND CONDITIONS

1. Services / Consideration.
Technology Networks Ltd. ('TechNet') shall develop an electronic version of the printed Application Note or Poster that has been created from the files provided by you (the 'Author'). In consideration of TechNet's development, archiving and retrieval of the Author's Application note, Author shall: (a) grant the license stated in Section 3.

2. Copyright Ownership.
As between TechNet and Author, Author shall be the owner of all copyrights in and to the content contained in the Print Application Note or poster and the online Application Note or Poster.

3. Copyright License.
In order for TechNet to electronically archive, display and distribute the Application Note or Poster, Author hereby grants to TechNet an irrevocable, perpetual license to maintain, store, cache, copy and distribute (in any current or future media) the Application Note or Poster (the 'License Grant'). The License Grant includes TechNet's right to include the Application Note or Poster in its current and future database or databases as well as to distribute the Application Note or Poster electronically to third parties through any one or more websites operated by or on behalf of TechNet.

4.Representations and Warranties.
Author hereby represents and warrants to TechNet that: (i) Author is the owner or authorized licensee of all right, title and interest (including all copyrights and other intellectual property rights) in and to all content that appears on the Application Note or Poster; (ii) all content that appears in the Application Note or Poster is the Author's original work and contains no libelous or unlawful statements, does not infringe on the rights or privacy of others or contain material or instructions that might cause harm or injury, (iii) Author's execution and performance of this Agreement does not and shall not constitute a breach of, or otherwise violate, any written or verbal understanding or agreement between Author and any third party; and (iv) TechNet's use of the files provided by the Author to create the Application Note or Poster, as well as TechNet's exercise of its rights pursuant to the License Grant, shall not infringe or violate the copyrights, or other intellectual property rights, of any third party.

5.Miscellaneous.
(a) This Agreement shall be construed and enforced in accordance with the laws of the United Kingdom. Each party hereby consents to the exclusive jurisdiction and venue of any court located in the United Kingdom with respect to any claim or controversy arising out of or related to this Agreement.

(b) This Agreement: (i) shall benefit and bind each party and their successors and assigns; (ii) contains the entire understanding and agreement of the parties; and it incorporates or supersedes all other written or verbal agreements and understandings with respect to the subject matter; and (iii) may be amended or modified only in writing signed by both parties and referring specifically to the Agreement.

Scientific News
BioCision Forms MedCision
The new company will focus on technologies for the management and automation of vital clinical processes.
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Study to Assess Shorter-Duration Antibiotics in Children
Physicians plan a clinical trial to evaluate whether short course anti-biotics are effective at treating CAP in children.
Cancer Gene Predicts Treatment Response in Leukaemia
Study indicates the patients suffering from a lethal for of acute myeloid leukemia may live longer when receiving milder chemotherapy drugs.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
Testing Zika Vaccine in Humans Begins
The first of five planned clinical trials to test ZPIV vaccine in humans has begun.
Combination Therapy Improved Chemoresistance in Ovarian Cancer
The study demonstrates how an existing class of targeted therapies could be used to potentiate the tumor suppression induced by cisplatin.
Gene Therapy for Blistering Skin Disease Shows Promise
Grafting genetically altered skin onto patients’ chronic wounds marks the first time skin-based gene therapy has been demonstrated to be safe and effective in humans.
Alzheimer’s Treatment Moves a Step Closer
Merck scientists have reported the discovery of verubecestat, a structurally unique, orally bioavailable small molecule that has been shown to target the most visible sign of the disease in the brain.
Lynparza Phase III Progression-Free Survival Benefit
AstraZeneca announces results from Phase III SOLO-2 trial designed to determine the efficacy of Lynparza as a monotherapy for ovarian cancer.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!